Percutaneous microwave ablation of hepatic lesions near the heart

Early stage liver cancer is often treated with hepatic resection or transplantation for curative intent. Microwave ablation (MWA) is often performed in patients who are poor surgical candidates, patients with limited multifocal disease, disease close to hepatic vasculature, but can also be performed with curative intent in case of small lesions. The purpose of this study is to evaluate safety and efficacy of MWA of liver tumors with final ablation zone ≤5 mm from the heart.

A retrospective review was conducted on patients with hepatic cancer who underwent MWA between 1/2015 and 6/2019. Patients with a final ablation zone ≤5 mm to the heart were included. For these patients, imaging obtained prior, during and after procedure along with procedure reports were used to identify tumor and ablation characteristics, and electronic medical records were used to identify patient demographics and disease status.

A total of 17 patients had liver tumors with ablation zone ≤5 mm to the heart. Mean lesion size was 18.2 mm (range, 10-33 mm) and mean follow-up period was 10.4 months. Of note 82% of patients had multifocal disease at time of MWA of lesion close to the heart. Two patients had pneumothorax, one of which required chest tube placement. None of the patients had cardiac arrhythmias or other complications. Overall 12/17 of the patients had disease progression within the liver at different sites from ablated lesions. One patient had residual disease and one had local recurrence. In addition, 4/17 patients, had no disease progression or recurrence and one underwent liver transplantation prior to follow-up imaging.

MWA of liver lesions with ablation zone ≤5 mm to the heart is safe and effective, however, it can be technically challenging.